Aarti Drugs Reports Strong Q2 FY27 Results with 83% YoY PAT Growth
Aarti Drugs Ltd 路 Press Release 路 04 Nov 2026, 2:47 am
Aarti Drugs Reports Strong Q2 FY27 Results with 83% YoY PAT Growth Aarti Drugs reported a solid Q2 FY27 performance, with consolidated revenue rising 27% YoY to Rs. 828.8 crore. EBITDA surged 63% YoY to Rs. 137.9 crore, expanding margins by 370 bps to 16.6%. PAT jumped 83% YoY to Rs. 82.8 crore, driven by strong realisations across API, Formulations (+58% YoY to Rs. 130 crore), and Specialty Chemicals (+92% YoY to Rs. 71.8 crore). In H1 FY27, revenue grew 23% YoY to Rs. 1,532.4 crore, while PAT rose 34% YoY to Rs. 132.9 crore.
Original exchange filing (PDF)
More announcements from Aarti Drugs Ltd
- Intimation of sad demise of Promoter and Chairman Emeritus of the Company 路 16 Nov 2026
- Transcript of Q2&H1 FY27 Earning Conference call 路 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requireents) Regulations, 2015 路 06 Nov 2026
- Audio recording for conference call for Analyst and Investors 路 05 Nov 2026
- Investor Presentation for Q2 FY27 路 04 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 04 Nov 2026
- Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 04 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 04 Nov 2026
